Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) shares traded 1.10% higher at $40.34 on Wall Street last session.
RARE stock price is now -9.59% away from the 50-day moving average and -4.23% away from the 200-day moving average. The market capitalization of the company currently stands at $3.35B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target of $77, RBC Capital Mkts recently initiated with Outperform rating for Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). On December 08, 2023, Wells Fargo recently initiated its ‘Overweight’ rating on the stock quoting a target price of $72, while ‘Credit Suisse’ rates the stock as ‘Outperform’
In other news, Crombez Eric, EVP and Chief Medical Officer sold 354 shares of the company’s stock on May 02 ’24. The stock was sold for $15,456 at an average price of $43.66. Upon completion of the transaction, the EVP and Chief Medical Officer now directly owns 48,431 shares in the company, valued at $1.95 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Apr 18 ’24, EVP and Chief Medical Officer Crombez Eric sold 142 shares of the business’s stock. A total of $6,262 was realized by selling the stock at an average price of $44.10. This leaves the insider owning 48,785 shares of the company worth $1.97 million. A total of 6.32% of the company’s stock is owned by insiders.
During the past 12 months, Ultragenyx Pharmaceutical Inc. has had a low of $31.52 and a high of $54.98. As of last week, the company has a debt-to-equity ratio of 6.65, a current ratio of 2.43, and a quick ratio of 2.28. The fifty day moving average price for RARE is $44.491 and a two-hundred day moving average price translates $42.137325 for the stock.
The latest earnings results from Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) was released for 2024-03-31. According to the Biotechnology Company, earnings per share came in at -2.25, missing analysts’ expectations of -2.07 by -0.18. This compares to -$2.33 EPS in the same period last year. The net profit margin was -138.58% and return on equity was -340.05% for RARE. The company reported revenue of $108.83 million for the quarter, compared to $100.5 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 8.3 percent. For the current quarter, analysts expect RARE to generate $122.77M in revenue.
